vimarsana.com

Latest Breaking News On - Erics daar - Page 3 : vimarsana.com

UMass Medical School researchers to evaluate treatment options for early COVID-19 infection

UMass Medical School researchers to evaluate treatment options for early COVID-19 infection UMass Medical School Communications July 08, 2021 UMass Medical School is participating in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial, which is being led by the AIDS Clinical Trials Group (ACTG). ACTIV-2 includes both Phase II and Phase III evaluations of investigational agents for treating early COVID-19. To qualify for ACTIV-2, participants must have tested positive for SARS-CoV-2 in the outpatient setting within 10 days and started experiencing symptoms within eight days of enrolling. “The goal of ACTIV-2 is to identify treatments that can keep people who acquire COVID-19 from getting sicker and requiring hospitalization,” said Robert W. Finberg, MD, distinguished professor of medicine and lead investigator of the Medical School’s ACTIV-2 trial site. “People living in central Massachusetts who have recently been diagnosed with COVID-19 a

ACTG announces the addition of two monoclonal antibodies to ACTIV-2 outpatient treatment study for COVID-19

 E-Mail Los Angeles, Calif. - The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced the addition of two monoclonal antibodies, BMS-986414 and BMS-986413, to the COVID-19 outpatient treatment study, ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial. BMS-986414 and BMS-986413 will be administered as subcutaneous injections (shots) given at one visit. ACTIV-2 includes both phase 2 and phase 3 evaluations of multiple investigational agents for treating early COVID-19 in a single trial. For information about enrolling in the trial, please visit the study website. Given that prevention and treatment will continue to be an important part of ending the COVID-19 pandemic, it is key that we identify and develop a variety of treatment options, said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles (UCLA). ACTIV-2 is studying a number of different therapeutic approaches, including infusions, shots, pi

Large NIH clinical trial will test polyclonal antibody therapeutic for COVID-19

HIN A Phase 2/3 trial to evaluate a new fully-human polyclonal antibody therapeutic targeted to SARS-CoV-2, called SAB-185, has begun enrolling non-hospitalized people with mild or moderate cases of COVID-19. The trial, ACTIV-2, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The therapeutic was developed by SAB Biotherapeutics, Inc. (Sioux Falls, South Dakota). NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program is a public-private partnership to develop a coordinated research strategy for speeding development of the most promising treatments and vaccine candidates. ACTIV-2 is a master protocol designed for evaluating multiple investigational agents in adults with mild-to-moderate COVID-19 who are not hospitalized. Led by the NIAID-funded AIDS Clinical Trials Group (ACTG) and supported by PPD (Wilmington, North Carolina), a global contract research organization that is re

Large NIH clinical trial will test polyclonal antibody therapeutic for COVID-19

Large NIH clinical trial will test polyclonal antibody therapeutic for COVID-19
nih.gov - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nih.gov Daily Mail and Mail on Sunday newspapers.

Four potential COVID-19 therapeutics enter Phase 2/3 testing

Four potential COVID-19 therapeutics enter Phase 2/3 testing Enrollment has begun to test additional investigational drugs in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program. ACTIV is a public-private partnership program to create a coordinated research strategy that prioritizes and speeds development of promising COVID-19 treatments and vaccines. The new agents entering the randomized, placebo-controlled study are part of ACTIV-2, an adaptive trial designed to test investigational agents in non-hospitalized adult volunteers experiencing mild to moderate COVID-19 symptoms. ACTIV-2 is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, and is led by the NIAID-funded AIDS Clinical Trials Group (ACTG).

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.